CyFlow CD22 APC
| 品番 | AY356030 | ||
|---|---|---|---|
| 抗体名 | Anti-Hu CD22 APC,S-HCL-1 | ||
| 包装単位 | 100 tests | ||
| 濃度 | - | ||
| 容量 | 1 ml | ||
| 関連製品 (アイソタイプコントロール) |
Mouse IgG2b APC (BS969970) |
||
| 反応性|交差吸着 | Human | レーザー | Red |
| 抗原 | CD22, SIGLEC2, SIGLEC-2, BL-CAM | 最大蛍光波長 | 660 nm |
| クローン | S-HCL-1 | 最大励起波長 | 650 nm |
| ホスト | Mouse | 標識/Format | APC |
| アイソタイプ | IgG2b | 研究分野 | Immunophenotyping |
| クローナリティ | monoclonal | 用途 | Flow cytometry |
Anti-Hu CD22 APC,S-HCL-1
特異性
The mouse monoclonal antibody S-HCL-1 (also known as S-HCL1) recognizes CD22 antigen, a 130 kDa type I transmembrane glycoprotein (immunoglobulin superfamily) expressed in the cytoplasm of pro-B and pre-B lymphocytes, and on the surface of mature and activated B lymphocytes; it is lost on plasma cells, peripheral blood T lymphocytes, granulocytes and monocytes.
抗原情報
CD22 (Siglec-2; sialic acid-binding immunoglobulin-like lectin-2) is a transmembrane glycoprotein binding α 2,6-linked sialic acid-bearing ligands. Intracellular domain of CD22 recruits protein tyrosine phosphatase SHP-1 through the immunoreceptor tyrosine-based inhibitory motifs (ITIMs), thus setting a treshold for B cell receptor-mediated activation. CD22 also regulates B-cell response by involvement in controlling the CD19/CD21-Src-family protein tyrosine kinase amplification pathway and CD40 signaling. CD22 exhibits hallmarks of clathrin-mediated endocytic pathway.
利用方法
The reagent is designed for Flow Cytometry analysis of human blood cells. Recommended usage is 10 µl reagent / 100 µl of whole blood or 10^6 cells in a suspension. The content of a vial (1 ml) is sufficient for 100 tests.
保存方法
Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
安定性情報
Do not use after expiration date stamped on vial label.
レファレンス
• Foon KA, Todd RF rd: Immunologic classification of leukemia and lymphoma. Blood. 1986·Jul; 68(1):11324. <·PMID:·2809561·>
• Huang J, Fan G, Zhong Y, Gatter K, Braziel R, Gross G, Bakke A: Diagnostic usefulness of aberrant CD22 expression in differentiating neoplastic cells of B‑Cell chronic lymphoproliferative disorders from admixed benign B cells in four‑color multiparameter flow cytometry. Am·J·Clin·Pathol. 2005·Jun; 123(6):826‑32. <·PMID:·15899772·>
• James SE, Greenberg PD, Jensen MC, Lin Y, Wang J, Till BG, Raubitschek AA, Forman SJ, Press OW: Antigen sensitivity of CD22‑specific chimeric TCR is modulated by target epitope distance from the cell membrane. J·Immunol. 2008·May·15; 180(10):7028‑38. <·PMID:·18453625·>
• Reineks EZ, Osei ES, Rosenberg A, Auletta J, Meyerson HJ: CD22 expression on blastic plasmacytoid dendritic cell neoplasms and reactivity of anti‑CD22 antibodies to peripheral blood dendritic cells. Cytometry·B·Clin·Cytom. 2009·Jul; 76(4):237‑48. <·PMID:·19382197·>
Available Safety Data Sheets
CyFlow™ monoclonal antibodies SDS CA EN